Filament Will License its Proprietary Botanical Psilocybin Drug Candidate, PEX010, to EntheoTech for Use in Clinical Trials Seeking Health Canada Approval VANCOUVER, BC, Nov. 18, 2021 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development company, today announced that it has entered into a co…


Previous articlePsychedelic Bypassing: When Avoidance is Mistaken for Healing
Next articleEyes on Oregon, a Psychedelics Today Podcast with Jon Dennis and Joe Moore